Works matching IS 09650407 AND DT 2020 AND VI 28 AND IP 5
Results: 11
Erratum.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Anticancer Activity of Novel NF-B Inhibitor DHMEQ by Intraperitoneal Administration.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 541, doi. 10.3727/096504020X15929100013698
- By:
- Publication type:
- Article
CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 533, doi. 10.3727/096504020X15919605976853
- By:
- Publication type:
- Article
Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2<sup>+</sup> Breast Cancer Cells to 5-Fluorouracil.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 519, doi. 10.3727/096504020X15960154585410
- By:
- Publication type:
- Article
miR-186 Represses Proliferation, Migration, Invasion, and EMT of Hepatocellular Carcinoma via Directly Targeting CDK6.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 509, doi. 10.3727/096504020X15954139263808
- By:
- Publication type:
- Article
Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 497, doi. 10.3727/096504020X15929939001042
- By:
- Publication type:
- Article
Long Noncoding RNA LINC02163 Accelerates Malignant Tumor Behaviors in Breast Cancer by Regulating the MicroRNA-511-3p/HMGA2 Axis.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 483, doi. 10.3727/096504020X15928179818438
- By:
- Publication type:
- Article
Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 467, doi. 10.3727/096504020X15925659763817
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
- Published in:
- Oncology Research, 2020, v. 28, n. 5, p. 451, doi. 10.3727/096504020X15898794315356
- By:
- Publication type:
- Article